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Abstract 
Background: Oral squamous cell carcinoma (OSCC) is the most common malignant tumour of the oral cavity. 
Detection of OSCC is currently based on clinical oral examination combined with histopathological evaluation of 
a biopsy sample. Direct contact between saliva and the oral cancer makes measurement of salivary metalloprotei-
nase- 9 (MMP-9) an attractive alternative.
Material and Methods: In total, 30 OSCC patients and 30 healthy controls were included in this prospective study. 
Saliva samples from both groups were collected, centrifuged and supernatant fluid was subjected to ELISA for 
assessment of MMP-9. The median salivary MMP-9 values with interquartile range (IQR) of OSCC patients and
the control group were statistically analysed using the Mann-Whitney U-test. The receiver operating characteris-
tic (ROC) curve was constructed and the area under curve (AUC) was computed.
Results: The median absorbance MMP-9 value of the OSCC group was 0.186 (IQR=0.158) and that of control 
group was 0.156 (IQR=0.102). MMP-9 was significantly increased in the OSCC patients than in the controls 
by +19.2% (p=0.008). Median values in patients with recurrence and in patients with primary event were 0.233 
(IQR=0.299) and 0.186 (IQR=0.134) respectively. MMP-9 was significantly increased in patients with primary 
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Introduction
More than 95% of oral cancers are squamous cell carci-
nomas (OSCC) (1). Despite great progress in cancer treat-
ment throughout the last several decades, the prognosis 
of OSCC is still poor. Although the oral cavity is easily 
accessible for direct visual examination, most OSCC pa-
tients are in an advanced stage, which is believed to be 
a major reason for the low survival rate of about 50 to 
63% (2-4). In contrast, early oral cancers are often highly 
curable with less morbidity than cancers that are in later 
stages (5). These statistics emphasise the importance of 
early and accurate detection by clinicians.
Currently, the detection and diagnosis of OSCC is based 
on clinical oral examination combined with histopatho-
logical evaluation of a biopsy sample. In response to the 
need for early detection of oral cancer, several diagnos-
tic adjuncts have been developed, including the use of 
salivary biomarkers (6-8). Collecting saliva is a rela-
tively simple procedure and is non-invasive, compared 
to biopsying or drawing blood.
To date, more than 100 potential OSCC salivary biomar-
kers have been suggested in the current literature (9). 
One of these potential biomarkers is metalloproteinase-
9 (MMP-9). MMP-9 is a class of enzymes that has been 
shown to be associated in cancer pathogenesis as they 
are involved in the degradation of extracellular matrix. 
Significant differences have been found in MMP-9 lev-
els between the OSCC patients and their respective con-
trol groups (10,11).
The purpose of this study was to determine the levels of 
MMP-9 in saliva of patients with OSCC and those in a 
healthy control group, and to investigate the diagnostic 
value of MMP-9.
Material and Methods
This prospective study was initiated after the local ethics 
committee of the Jena University Hospital gave its approv-
al (4369-03/15). Informed written consent was obtained 
from all individual participants included in the study.
- Collection of samples
A tissue biopsy sample for histological examination was 
obtained from patients with potentially malignant dis-
ease after the salvia collection. If a biopsy sample was 
negative in the experimental group, the patient was
excluded from the study.
event (p=0.017) compared to controls by +19.2%. No significant increase of MMP-9 level was detected when com-
paring patients with recurrence and healthy controls (+49.4%; p=0.074). The sensitivity value of MMP-9 was 100% 
whereas the specificity value was 26.7% with AUC of 0.698.
Conclusions: The present data indicates that the elevation of salivary levels of MMP-9 may be a useful adjunctive 
diagnostic tool for detection of OSCC. However, further studies are necessary to provide scientific and clinical vali-
dation.
Key words: Oral squamous cell carcinoma, oral cancer, saliva, salivary diagnostics, cancer detection, MMP-9, 
metalloproteinases.
A total of 60 samples were included in the dataset, in-
cluding 30 cases of OSCC and 30 of healthy individu-
als.The controls were gender and age-matched subjects 
enrolled during the same period when OSCC subjects 
were recruited. Controls were generally healthy indi-
viduals free from any systemic disease, cancer or in-
flammatory oral lesions.
- Study population
The demographic data of all subjects included in this 
study and the tumour clinicopathological parameters of
patients with OSCC are listed in table 1. The data ob-
tained included age, gender, tumour site, tumour stage 
according to the TNM classification of the International 
Union against Cancer (UICC) and histological tumour 
grade.
Among the 30 OSCC patients of the study group, 16 
were females and 14 were males. The mean age was 
65.0±10.9 years (mean±SD) with a range from 49 to 90.
The control group included 12 females and 18 males, 
mean age 60.7±12.3 years (range 35-85).
- Saliva collection and immunoreactivity assay for sali-
vary
In both groups, saliva was collected in the morning be-
tween 7 and 8 o’clock before food intake. Stimulated sa-
liva samples were collected using Salivette® (Sarstedt, 
Nuernbrecht, Germany). Patients were asked to make 
chewing motions for 30 seconds to stimulate saliva pro-
duction.
MMP-9 concentrations were measured by immunoreac-
tivity assay similar to the method previously described 
(10,11). In brief, following the collection, the saliva was
immediately centrifuged at 1,000 g at 20°C for 2 min 
and the resulting supernatant was used to determine the 
total amount of total protein with BCA Protein Assay 
Kit (Thermo Scientific, Rockford, IL, USA) as specified 
by the manufacturer.
After calculation of the concentration of total protein, a
solution with 10 ng total protein pro μl of each sample 
was made by diluting the saliva with PBS (Invitrogen, 
Camarillo, CA, USA). Thereafter, 100 μl of each sample 
was added to Nunc Immuno Plate wells (Thermo Fisher 
Scientific Nunc A/S, Roskilde, Denmark). The plate 
was covered and stored overnight at 4°C.
The next day, each well was washed 3 times with 100 μl 
PBS-T (PBS containing 0.05% Tween 20) and a volume 
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of 100 μl blocking solution (PBS-T containing 1% BSA) 
was added to each well. After 2 hour incubation at room 
temperature, the blocking solution was removed and 
100 μl of primary antibody (polyclonal rabbit anti hu-
man MMP-9, biorbyt, San Francisco, CA, USA) diluted 
1:20,000 in blocking solution was added to each well. 
After another 2 hour incubation at room temperature, 
the plate was washed as described before and a volume 
of 100 μl of secondary antibody (peroxidase-conjugated 
goat anti-rabbit IgG, Jackson Immuno Research, West 
Grove, PA, USA) diluted 1:5,000 in blocking solution 
was added to each well. Finally, after a third 2 hour 
incubation period at room temperature the plate was 
washed as described before. To achieve colour develop-
ment, 100 μl of 3.3 ,` 5.5`-tetramethylbenzidine solution 
(Southern Biotech, Birmingham, AL, USA) was added 
to each well. After 2 min, 100 μl of TMB Stop Solution 
(Southern Biotech, AL, Birmingham, USA) was added 
to each well. Absorbencies of the samples, representing 
the levels of MMP-9, were measured at a wavelength of 
450 nm directly after the addition of the Stop Solution, 
using a ThermoMax microplate reader (Molecular De-
vices, Sunnyvale, CA, USA).
- Statistical analysis
The nonparametric Mann-Whitney U test was used 
Table 1: Demographic and Clinical Data of Subjects.
to compare the differences in the median absorbance 
values in the groups. Receiver operating characteristic 
(ROC) curves were used to evaluate the diagnostic ef-
fectiveness of the potential biomarker and to find an op-
timal cut-off point based on the maximum correspond-
ing sensitivity and specificity. Furthermore, the area 
under curve (AUC) presented a direct measure of the 
diagnostic accuracy of the test. Levels of statistical sig-
nificance have been calculated at the 5% level of prob-
ability (p <0.05). Statistical analyses were performed 
using SPSS 21.0 for Windows (Chicago, IL).
Results
The saliva analysis showed differences in the level of 
MMP-9. The median absorbance value in controls was 
0.156 with interquartile range (IQR) of 0.102. In con-
trast, the median absorbance value in the study group 
was 0.186 (IQR=0.158). Thus, MMP-9 was significantly 
increased in the OSCC patients by +19.2% (p=0.008).
(Fig. 1) shows box plots of the two groups. Further-
more, median absorbance values in patients with recur-
rence and in patients with primary event were 0.233 
(IQR=0.299) and 0.186 (IQR=0.134), respectively. In 
patients with primary event, MMP-9 was significantly 
higher by +19.2% (p=0.017) compared to controls. In 
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contrast, no significant differences of MMP-9 levels 
were seen when comparing patients with recurrence 
and healthy controls (+49.4%; p=0.074).
As shown in fig. 2, the ROC curve was created to dem-
onstrate the predictive power of MMP-9 for OSCC. The 
AUC was 0.698 (cut off value > 0.104; sensitivity 100%; 
specificity 26.7%; 95% confidence interval, 0.567-0.830; 
p=0.008) for OSCC patients vs. healthy controls.
Fig. 1: Box plots of median absorbance MMP-9 values from the OSCC patients and the 
controls. Salivary MMP-9 was significantly increased in the OSCC patients compared 
to the control group (p=0.008).
Fig. 2: ROC analysis of salivary MMP-9 in diagnosis of OSCC for the OSCC 
patients vs. healthy controls.
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Discussion
Most OSCCs are found when the cancer has developed 
into the advanced stages, which is believed to be a major 
reason for low survival rates (2-4). In contrast, early de-
tection and diagnosis leads to a greater survival rate and 
plays an important role in successful clinical treatment 
(5). Early diagnosis of OSCC is difficult because the early 
stages may be painless and often a burning sensation may 
not develop until the malignant lesion has appreciably ad-
vanced (5,12). Detection and diagnosis of OSCC is cur-
rently based on clinical oral examination combined with 
biopsy for a histopathological examination if a suspect 
area is detected (1). The location from which the tissue bi-
opsy sample is taken is essential for histological verifica-
tion of the oral cancer. However, selecting the correct site 
for biopsy is difficult due to the non-uniform appearance 
of premalignant and malignant lesions (5,12).
Today, the presence of OSCC salivary biomarkers is 
well known based on the direct contact between saliva 
and the premalignant or malignant lesions. Saliva sam-
pling and processing is a simple procedure and is a more 
easily accessible fluid than tissue biopsies and blood 
sampling. Furthermore, saliva sampling eliminates 
risks of contamination and infection (10). The screen-
ing and detection of early OSCC lesions using saliva 
seems to be promising. Currently, more than 100 poten-
tial salivary biomarkers have been reported in the litera-
ture (9). In the present study, we analyzed the levels of 
MMP-9 in saliva of patients with OSCC and in saliva of 
patients in the healthy control group. MMP-9 is a class 
of zincdependent proteinases (13) that have been shown 
to associate in numerous pathological processes as they 
degrade type IV collagen, a major component of the 
basal lamina, and other types of collagens (V, VII and 
X), elastin and fibronectin. Studies have reported a high 
expression in stromal cells surrounding the invading 
front of metastasizing tumours. In addition, an eleva-
tion of their levels in tumour endothelium and in urine 
of cancer patients has been found (14-16). Furthermore, 
MMP-9 may play a significant role in angiogenesis (17-
19). Thomas et al. showed that MMP-9 expression in 
vitro is modulated by integrin alpha v beta 6, which is 
expressed only in OSCC and not in the normal oral epi-
thelium (20). Kosunen et al. reported that strong stro-
mal MMP-9 staining intensity was correlated with poor 
tumour differentiation (21).
In our study, MMP-9 level in the OSCC patients com-
pared to healthy controls was altered in a highly signifi-
cant manner (+19.2%). Furthermore, it was character-
ised by high sensitivity (100%) and moderate specifi-
city (26.7%) values. The current data showed a cut off 
value of > 0.104. This means that cases above these cut 
off values can be diagnosed as having OSCC, whereas 
cases below these values can be diagnosed as negative 
(healthy) cases.
Shpitzer et al. corroborated these results, as they also 
note that MMP-9 increased in OSCC patients compared 
to controls by 35% to 39% (10,11). Thus, MMP-9 could 
be used as a diagnostic adjunct for early detection of 
oral cancer.
Patients with OSCC have a high risk of tumour relapse.
In the current literature, a recurrence rate from 29.8% to 
47.1% has been reported (22-24) with local recurrence 
being more common (22). Therefore, an improved di-
agnostic tool to predict which patient is most at risk for 
tumour relapse is needed (25). In addition to clinical ex-
aminations and routine imaging modalities such as ul-
trasonography, computed tomography or magnetic reso-
nance imaging (22), salivary MMP-9 could be of special 
importance for patient monitoring during follow-up. In 
the present study, median absorbance MMP-9 value in 
patients with recurrence was highly increased by 49.4% 
compared to healthy controls, but there was no signifi-
cant difference (p=0.074). Thus, measuring salivary 
MMP-9 levels cannot be recommended in the routine 
diagnostic assessment for tumour recurrence during 
follow-up.
Conclusions
Salivary diagnostics for OSCC are very promising 
due to the direct contact of saliva with oral cancer le-
sions. MMP-9 seems to play an important role in OSCC 
pathogenesis. The results of the present study suggested 
that cancer-related changes in salivary MMP-9 could be 
used as a tool for early detection of OSCC. Further stud-
ies in large patient cohorts are necessary before salivary 
MMP-9 might be used in future clinical diagnostic ap-
plications.
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